Finanzen von enVVeno Medical Corp (NVNO)NVNOenVVeno Medical Corp

Evaluating the bottom line, enVVeno Medical Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -58.53%, provide a clear picture of how effectively NVNO converts its operational activities into shareholder value.

In the context of the broader market, NVNO competes directly with industry leaders such as NDRA and CELZ. With a market capitalization of $7.97M, it holds a significant position in the sector. When comparing efficiency, NVNO's gross margin of N/A stands against NDRA's N/A and CELZ's N/A. Such benchmarking helps identify whether enVVeno Medical Corp is trading at a premium or discount relative to its financial performance.

The company has consistently reported net losses, with the latest figures showing a net income loss of $3,600,000 in Q2 2026. The EPS has been negative, with a reported EPS of -5.37 in the last quarter, indicating ongoing financial difficulties.